Calcium folinate pentahydrate
Gastrointestinal Carcinoid Tumor
Mayo ClinicSmall moleculePhase 2/3Dormant
BB
68/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 55/ 100
- Competitive Position
- 95/ 100
Competitive context
3 Active assets in the Gastrointestinal Carcinoid Tumor cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
FLUOROURACILUM Mayo Clinic | Phase 2/3 | BB |
Irinotecan National Cancer Institute (NCI) | Phase 3 | BB |
Octreotide Pamoate National Cancer Institute (NCI) | Phase 3 | BB |
(+)-VINCRISTINE National Cancer Institute (NCI) | Phase 3 | BB |
Eloxatin Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS | Phase 2/3 | BB |
View all 24 →
Same molecule, other indications
Calcium folinate pentahydrate is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →